Affirm Holdings, Inc. (AFRM) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001820953 · SEC filings checked Oct 18, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 27, 2026 | $387.5M | $1.62B | $4.63 | Filing |
| Mar 31, 2026 | May 7, 2026 | $334.5M | $102.9M | $0.30 | Filing |
| Dec 31, 2025 | Feb 5, 2026 | $401.4M | $129.6M | $0.37 | Filing |
| Sep 30, 2025 | Nov 6, 2025 | $320.5M | $80.7M | $0.23 | Filing |
| Jun 30, 2025 | Aug 28, 2025 | $306.6M | $69.2M | $0.22 | Filing |
| Mar 31, 2025 | May 8, 2025 | $272.5M | $2.8M | $0.01 | Filing |
| Dec 31, 2024 | Feb 6, 2025 | $303.0M | $80.4M | $0.23 | Filing |
| Sep 30, 2024 | Nov 7, 2024 | $231.8M | $-100.2M | $-0.31 | Filing |
What would Affirm Holdings, Inc. have to report for its valuation to change?
At $74.01, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 2.7% a year, to $6.33. On that path the next quarter needs diluted EPS near $0.24, against $0.23 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 2.7% | 2.7% |
| EPS needed in final year | $6.33 | $6.33 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. AFRM goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.